CapyFin

Loading...

CapyFin Real-time Earnings Reports.

Products

Earnings

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

© 2025 CapyFin. All rights reserved.

Disclaimer: This platform provides information and recommendations for educational purposes only and is not a substitute for professional financial advice. Our content covers a range of investment classes, including stocks and cryptocurrencies, and we do not guarantee the completeness, accuracy, reliability, or suitability of this information, which may include data from third-party services and content generated by artificial intelligence (AI). Investing in stocks, cryptocurrencies, and other financial instruments involves risks, including the potential loss of principal. Users should independently verify all information and seek advice from qualified professionals tailored to their individual financial situations and investment objectives. Our content and services are provided "as is" without any warranties, express or implied. We are not liable for any losses or damages arising from the use of our services. This disclaimer is subject to change; users are advised to review it periodically. Usage of our services constitutes acceptance of these terms.

🇺🇸 NASDAQ:CRVO

Overview Earnings Dividends

Nov 14, 2022

•

Sep 30, 2022

CervoMed Q3 2022 Earnings Report

Provided an update on the strategic opportunities and its 2022 annual meeting of stockholders.

Key Takeaways

Diffusion Pharmaceuticals is actively pursuing a strategy to deliver stockholder value, including a possible sale, merger, or recapitalization. The company is in active bidding stage but the Board rejected an unsolicited offer from a LifeSci Capital client as inadequate, leading to a proxy contest.

Diffusion is evaluating strategic opportunities to enhance stockholder value.

The company is in the active bidding stage and encouraged by the response to the Strategic Review Process.

The Board rejected an unsolicited offer from a LifeSci Capital client.

LifeSci commenced a proxy contest for control of the Diffusion Board.

EPS

-$1.37

Previous year: -$2

-31.5%

Cash and Equivalents

$6.59M

Previous year: $40.3M

-83.7%

Total Assets

$26.3M

Previous year: $40.9M

-35.6%

CervoMed

CervoMed

Company Overview

Full financial data and analysis